<DOC>
	<DOCNO>NCT02879877</DOCNO>
	<brief_summary>This study design evaluate safety tolerability UCB7858 give single ascend dos administer intravenous subcutaneous infusion healthy subject .</brief_summary>
	<brief_title>A First-In-Human Study With Single Ascending Dose UCB7858 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer give write consent signing Informed Consent Form Subjects age 18 55 year old normal weight determine body mass index ( BMI ) 18 30 kg/m^2 , body weight least 50 kg male subject 45 kg female subject Subject clinical laboratory test result within reference range test laboratory ( include normal renal liver function ) test result outside specified range deem clinically nonsignificant Subjects blood pressure ( BP ) pulse within normal range supine position 5 minute rest Subject 's electrocardiogram ( ECG ) consider 'normal ' 'abnormal ' clinically nonsignificant Subject medical psychiatric condition , opinion Investigator , could jeopardize would compromise subject 's ability participate study : Subject acute chronic illness , opinion Investigator , may place subject risk participation study . Subject clinically relevant abnormal finding physical examination , laboratory test , vital sign , ECG , , opinion Investigator , may place subject risk participation study . Tests positive Human Immunodeficiency Virus ( HIV ) 1 or2 antibody , Hepatitis B Virus ( HBV ) surface antigen , Hepatitis C Virus ( HCV ) antibody Hepatic impairment Renal impairment Any follow hematological function test Screening Visit : Hemoglobin &lt; 111g/L ( woman ) &lt; 113g/L ( men ) ; Absolute neutrophil count &lt; 1.5x10^9/L ( &lt; 1000/mm^3 ) ; Platelets &lt; 150x10^9/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>First human</keyword>
	<keyword>subject</keyword>
</DOC>